key: cord-0884706-1lt1u46j
authors: Beghi, Ettore; Helbok, Raimund; Ozturk, Serefnur; Karadas, Omer; Lisnic, Vitalie; Grosu, Oxana; Kovács, Tibor; Dobronyi, Levente; Bereczki, Daniel; Cotelli, Maria Sofia; Turla, Marinella; Davidescu, Eugenia Irene; Popescu, Bogdan Ovidiu; Valzania, Franco; Cavallieri, Francesco; Ulmer, Hanno; Maia, Luis F.; Amodt, Anne Hege; Armon, Carmel; Brola, Waldemer; Victoria, Gryb; Riahi, Anis; Krehan, Ingomar; von Oertzen, Tim; Azab, Mohammed A; Crean, Michael; Lolich, Maria; Lima, Maria João; Sellner, Johann; Perneczky, Julian; Jenkins, Tom; Meoni, Sara; Bianchi, Elisa; Moro, Elena; Bassetti, Claudio L. A.
title: Short‐ and long‐term outcome and predictors in an international cohort of patients with neuro‐COVID‐19
date: 2022-03-07
journal: Eur J Neurol
DOI: 10.1111/ene.15293
sha: 42a6e56cb552961f528c47dd8316826fb020aefa
doc_id: 884706
cord_uid: 1lt1u46j

BACKGROUND AND PURPOSE: Despite the increasing number of reports on the spectrum of neurological manifestations of COVID‐19 (neuro‐COVID), few studies have assessed short‐ and long‐term outcome of the disease. METHODS: This is a cohort study enrolling adult patients with neuro‐COVID seen in neurological consultation. Data were collected prospectively or retrospectively in the European Academy of Neurology NEuro‐covid ReGistrY ((ENERGY). The outcome at discharge was measured using the modified Rankin Scale and defined as ‘stable/improved’ if the modified Rankin Scale score was equal to or lower than the pre‐morbid score, ‘worse’ if the score was higher than the pre‐morbid score. Status at 6 months was also recorded. Demographic and clinical variables were assessed as predictors of outcome at discharge and 6 months. RESULTS: From July 2020 to March 2021, 971 patients from 19 countries were included. 810 (83.4%) were hospitalized. 432 (53.3%) were discharged with worse functional status. Older age, stupor/coma, stroke and intensive care unit (ICU) admission were predictors of worse outcome at discharge. 132 (16.3%) died in hospital. Older age, cancer, cardiovascular complications, refractory shock, stupor/coma and ICU admission were associated with death. 262 were followed for 6 months. Acute stroke or ataxia, ICU admission and degree of functional impairment at discharge were predictors of worse outcome. 65/221 hospitalized patients (29.4%) and 10/32 non‐hospitalized patients (24.4%) experienced persisting neurological symptoms/signs. 10/262 patients (3.8%) developed new neurological complaints during the 6 months of follow‐up. CONCLUSIONS: Neuro‐COVID is a severe disease associated with worse functional status at discharge, particularly in older subjects and those with comorbidities and acute complications of infection.

| 1665 OUTCOME OF NEURO-COVID AND PREDICTORS acute phase) and find outcome predictors; (2) to illustrate the demographic and clinical features of inpatients and outpatients with neuro-COVID from different countries; (3) to define incidence and types of new neurological manifestations after the acute phase.

A multinational registry of patients with neuro-COVID was activated in May 2020 by the European Academy of Neurology (EAN) to provide epidemiological data on neurological signs and symptoms in patients with COVID-19 infection reported by neurologists in outpatient services, emergency rooms and hospital departments (the EAN NEuro-covid ReGistrY, ENERGY). Details on the ENERGY structure and organization have been published [15] .

Briefly, all neurologists participating in the registry were asked to record neurological symptoms, signs and diagnoses in clinically or laboratory-confirmed COVID-19 patients in an electronic case record form (e-CRF) (Appendix S1). Data were collected prospectively or retrospectively and included patients' demographics and lifestyle habits, comorbidities, date of first symptoms of infection, hospital and intensive care unit (ICU) admission, incident general and neurological manifestations during the acute phase, diagnostic tests and outcome. Each variable was reported as 'Yes ', 'No' or 'Unknown'. In addition, for each documented neurological manifestation, the local investigator was asked to indicate whether or not it was associated with COVID-19.

All adult patients with symptoms and/or signs and/or diseases requiring neurological consultation were eligible for inclusion. A guide is included in the e-CRF (Appendix S2) to define each variable and facilitate data collection in the e-CRF at study entry and during follow-up. Registration and follow-up of eligible patients is ongoing.

All registered patients were followed through telephone contacts at 6 and 12 months. At each contact, the modified Rankin Scale (mRS) score was assigned and new neurological manifestations were noted; for patients who died, date of death and, if performed, autopsy were noted. As the mRS is reliable even when applied by telephone [16] , in addition to follow-up, functional disability at baseline was measured enquiring of patients or caregivers their pre-morbid functional status.

Descriptive statistics were performed on all variables collected during the acute phase in the entire sample and comparing hospitalized and non-hospitalized patients and prospective and retrospective observations. The outcome of the infection, in terms of functional impairment, was defined as 'stable/improved' if mRS at discharge was equal to or lower than the baseline score; 'worse' if mRS score at discharge was higher than the baseline score. Stable/ improved and worse outcome were also assessed in patients who died during hospital stay compared to those discharged alive.

Neurological symptoms, signs and diagnoses persisting at 6 months were listed. The demographic and clinical profile of patients with new neurological manifestations occurring during follow-up was illustrated. The same methods were used to assess the effect of variables collected during the acute phase or at discharge on the 6-month outcome.

The association of all variables included in the registry with outcome (worse vs. stable/improved) and status (dead vs. alive) at hospital discharge was evaluated using univariable logistic regression models. Variables identified as statistically significant in univariable models were included in multivariable models, and a stepwise selection (with p < 0.05 as the criterion for entering and removing effects) was applied to identify variables most strongly associated with the outcome and status at discharge. Results of univariable and multivariable logistic regression models are presented as odds ratios (ORs) and adjusted odds ratios with 95% confidence intervals (CIs).

Significance was set at the 5% level (0.05).

For demographic and lifestyle variables, mRS and outcome, the number of missing data was reported in the tables and indicated as unknown or missing. For all other variables, 'unknown' values were grouped with 'No'. For neurological findings, the categories 'present, not COVID associated' and 'present, likely COVID associated' were combined. Data presented as numbers with percentages or as means with standard deviations or medians and ranges were calculated only in subjects with the corresponding values.

The study was approved by the ethics committees of all participating sites and informed consent was obtained from all eligible patients in line with each participating country's legal requirements.

As of 31 March 2021, 1004 patients were enrolled. COVID-19 infection was not laboratory-confirmed in 33 cases, which were excluded from further analyses. The final sample included 971 patients from 19 countries (Europe 14; Asia 2; Africa 2; South America 1) ( Table 1) .

A flowchart of the study is illustrated in Figure 1 .

With few exceptions, there were no major differences in the general characteristics of prospective compared to retrospective cases (Table S1) Worse outcome, mRS score at discharge higher than pre-morbid mRS score; stable/improved outcome, mRS score at discharge equal to or lower than pre-morbid mRS score.

non-hospitalized subjects). 432 hospitalized patients (53.3%) were discharged with a worse functional status compared to admission ( Abbreviations: BMI, body mass index; ICH, intracerebral haemorrhage; ICU, intensive care unit; IQR, interquartile range; mRS, modified Rankin Score; TIA, transient ischaemic attack.

a Worse outcome, mRS score at discharge higher than pre-morbid mRS score; stable/improved outcome, mRS score at discharge equal to or lower than pre-morbid mRS score. a Worse outcome, mRS score at discharge higher than pre-morbid mRS score; stable/improved outcome, mRS score at discharge equal to or lower than pre-morbid mRS score.

This is the largest international cohort study including 6-month follow-up in adult patients with neuro-COVID seen by neurologists. It was found that neurological complications are highly prevalent and have a dramatic impact on the outcome of hospitalized patients.

Further strengthening the relevance of neurological involvement, a 76% persistence of neurological involvement was found with mildto-severe functional impact in 68%. shock were associated with increased mortality. Older age and coma were negative prognostic predictors (increased functional disability and death) but did not predict worse outcome at 6 months amongst survivors at discharge. ICU admission was a negative prognostic factor both at discharge and at 6 months.

At 6 months, 28.6% of patients still presented persistent neurological sequelae of the acute phase, the commonest being focal or generalized motor weakness and cognitive impairment. The development of stroke or ataxia, ICU admission and functional impairment at discharge were predictive of worse 6-month outcome.

These findings support the dispute that only the severity of the acute COVID-19 spectrum and some neurological complications, rather than older age, the presence of comorbidities and the baseline functional impairment, are significant long-term prognostic predictors.

A number of neurological symptoms or signs (hyposmia/hypogeusia, syncope, dystonia, history of stroke) were associated with stable/improved outcome. However, for some of them (hyposmia/ hypogeusia, syncope, dystonia) interview bias is a possible explanation (as more severe cases were perhaps unable to report those symptoms). The protective role of history of stroke cannot be easily interpreted. Although the mechanisms of previous strokes might have been different from COVID-19's mechanism of action, a coincidental finding cannot be excluded.

Another study assessed incident neurological symptoms, signs and diagnoses in 4491 hospitalized patients seen in neurological consultation [17] . In that study, 88% of patients had new neurological manifestations. The most common were toxic/metabolic encephalopathy (51%), stroke (14%), seizures (12%) and hypoxic/ischaemic brain injury (11%). In line with our study, those patients were older, more severely ill and less likely to be discharged home.

Our findings differ from other reports. In a large retrospective cohort (N = 236,379) using data from an electronic health records network [9] , the estimated incidence of neurological or psychiatric diagnoses at 6 months following the acute phase of COVID-19 was 33.6% (first diagnosis, 12.8%). The commonest neurological diseases were, in decreasing order, stroke (2.7%), dementia (0.7%) and parkinsonism (0.1%). Our higher rates can be explained by the source of our cases (80% hospitalized) and by patients seen in neurological consultation. However, in line with us, the incidence of stroke and dementia were significantly higher in patients with more severe disease.

In a prospective study of 4182 incident cases of COVID-19

who self-reported their symptoms using a mobile application, 558 participants (13.3%) experienced symptoms lasting ≥28 days, 189 (4.5%) for ≥8 weeks and 95 (2.3%) for ≥12 weeks [8] . The commonest were fatigue, headache, dyspnoea and anosmia and they were more frequent with increasing age, body mass index and female sex.

The presence of more than five symptoms during the first week of illness was associated with prolonged complaints during follow-up.

This is in line with our study and suggests that the higher severity of the disease is the consequence of a multisystem involvement by the virus, as shown by others [18] Post-hospital persistent symptoms (including memory loss

[34%], concentration and sleep disorders [28% and 30%]) were reported during phone calls by 279 patients who had COVID-19 [6] .

Although some study limitations (single centre, inclusion of patients without neurological complaints, high attrition rate) can explain the differences with our findings, the frequent report of cognitive impairment and sleep disorders indicated similarities.

In a study including 1733 of 2469 discharged patients with a median follow-up of 6 months, fatigue or muscle weakness (63%) and

sleep difficulties (26%) were the commonest persistent symptoms [13] . Twenty-four per cent of cases reported a median 6-min walking distance less than the lower limit of the normal range. Compared to our study, these higher rates might be explained by high attrition (736 patients, perhaps the least severe cases, did not attend follow-up appointments).

In a population-based cohort study including non-hospitalized subjects, 938 subjects were invited to participate in a postal survey and 48% responded. Although the interviewees reported reduction of symptoms 1.5-6 months after the acute phase, 16% manifested persisting dyspnoea, 12% dysosmia and 10% dysgeusia [7] . The differences between this study and ours are reflected, on one side, by our longer follow-up and, on the other side, by the possible underascertainment of non-neurological manifestations in our study or under-ascertainment of neurological complaints in that study.

Sequelae at 6 months were reported in a prospective cohort study by 32.8% of 177 adults recovering from COVID-19 [11] . Worse outcome, mRS score at discharge higher than pre-morbid mRS score; stable/improved outcome, mRS score at discharge equal to or lower than pre-morbid mRS score.

clinical assessment of the patient was to be completed according to a detailed checklist (Appendix S1). The major limitation of our study is the lack of a population base. It was attempted to define the reference population to estimate incidence and prevalence of the various neurological manifestations. However, the differing catchment areas served by the participating sites did not consent precise calculations.

Another important limitation is the focus on neurological manifestations. Eligible patients were those seen in neurological consultation.

Although efforts were made to collect information on all comorbidities with impact on patients' health and the major complications of COVID-19, our investigation of the full spectrum of the disease has been incomplete. Then, diagnostic accuracy was not always high as a more detailed assessment of registered patients (results of neuropsychological and imaging tests, treatments) was not required to avoid a time consuming data collection, given the emergency context in which neurological consultation was performed. It was also chosen not to collect data on treatments as they were rarely supported by evidence-based recommendations. Finally, the use of mRS at discharge to predict functional disability at home or in residential or rehabilitation settings could be debated.

In conclusion, in a multinational cohort of patients with neuro-COVID undergoing structured neurological consultation, a severe disease was found in a high proportion of patients. The presence of severe infection with complications predicted worse outcome at discharge, persistence of functional disability, and a number of sequelae at 6 months follow-up, some of those occurring after the remission or stabilization of the acute phase of the disease. Patients with neurological manifestations during the acute phase of COVID-19 infection should be carefully monitored to prevent the occurrence of long-term complications and premature mortality.

PhD for their valuable intellectual support to the organization of the ENERGY registry, to Lalit Kaltenbach for the preparation of the web database, to Ms Anja Sander for her assistance during the activation and conduct of the ENERGY registry, and all participating patients. 

Serefnur Ozturk: Conceptualization (equal); writing-original draft (equal); writing-review and editing (equal)

Vitalie Lisnic: Conceptualization (equal); supervision (equal); writing-original draft (equal)

Maria Sofia Cotelli: Conceptualization (equal); supervision (equal); writing-original draft (equal). Eugenia Irene Davidescu: Conceptualization (equal); writing-original draft (equal)

Francesco Cavallieri: Conceptualization (equal); supervision (equal); writing-original draft (equal)

Ingomar Krehan: Conceptualization (equal); data curation (equal); writing-original draft (equal). Tim J von Oertzen: Conceptualization (equal); data curation (equal); supervision (equal). Mohammed Azab: Conceptualization (equal); data curation (equal); supervision (equal). Michael Crean: Conceptualization (equal); data curation (equal); supervision (equal)

data curation (equal); supervision (equal); writing-original draft (equal)

Julian Perneczky: Conceptualization (equal); data curation (equal); supervision (equal); writing-original draft (equal). Thomas M Jenkins: Conceptualization (equal); data curation (equal); supervision (equal)

Conceptualization (equal); data curation (equal)

Elisa Bianchi: Conceptualization (equal); data curation (equal); formal analysis (equal); software (equal); writing-original draft (equal); writingreview and editing (equal)

Claudio L Bassetti: Conceptualization (equal); data curation (equal); funding acquisition (lead); supervision (equal)

Data can only be shared with permission of individual countries

Tibor Kovács

Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID consortium and the ENERGY consortium

Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature

Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions

Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

COVID-19 Neuro Research Coalition. Approaches to understanding COVID-19 and its neurological associations

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study

Attributes and predictors of long COVID

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

Sequelae in adults at 6 months after COVID-19 infection

Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study

Sixtyday outcomes among patients hospitalized with COVID-19

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19

Reliability of the modified Rankin Scale applied by telephone

A prospective study of neurologic disorders in hospitalized patients with COVID-19 in

Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study

Short-and long-term outcome and predictors in an international cohort of patients with neuro-COVID-19